Literature DB >> 3994149

Bronchodilators increase airway instability in cystic fibrosis.

M S Zach, B Oberwaldner, G Forche, G Polgar.   

Abstract

Supramaximal flow transients of partial expiratory flow-volume curves are caused by a rapidly emptying compartment. By superimposing a maximal and a series of partial expiratory flow-volume curves, the volume of the flow transient equivalent for the maximal curve was estimated (volume of airway contribution = VACMEFV). This flow transient equivalent is caused by an extra dead space, created in the large airways by a full inspiration. In 18 children with cystic fibrosis (CF), routine pulmonary functions and VACMEFV were measured before and after bronchodilator medication. Baseline VACMEFV correlated directly with the curvilinearity of the flow-volume curve and inversely with the clinical and radiologic score. Significantly, bronchodilator medication improved FVC, FEV1, FEF25-75, VC, PEF, Raw, and also VACMEFV. In 6 children, VEmax25 increased as a result of apparent peripheral bronchodilation. In 3 others, end-expiratory flow increased slightly but the expanded VACMEFV included the measuring point invalidating the measurement. In the remaining 9 patients, VEmax25 decreased after bronchodilator. As an apparent discrepancy, FEV1, FVC, PEF, VC, FEF25-75 increased, and Raw decreased in 4 to 9 patients. The volumes and flow rates measured early in forced expiration and the end-expiratory flow behaved differently because VACMEFV expanded beyond the measuring points of early expiratory and mid-expiratory flow rates. As the bronchodilator rendered the compliant large airways still more distensible, the amount of air emptied from the dead space in early forced expiration increased. Simultaneously, end-expiratory flow decreased because of enhanced airway compression.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994149     DOI: 10.1164/arrd.1985.131.4.537

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

Review 1.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 2.  Pathogenesis and management of lung disease in cystic fibrosis.

Authors:  M S Zach
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

Review 3.  Airway reactivity in cystic fibrosis.

Authors:  R S Tepper; H Eigen
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.

Authors:  S P Conway; A Watson
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

5.  Variable response to inhaled salbutamol of different lung function parameters in healthy children.

Authors:  F Riedel; H von der Hardt
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 6.  Acute viral bronchiolitis in infancy: epidemiology and management.

Authors:  T Nicolai; A Pohl
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 7.  Chest physiotherapy--the mechanical approach to antiinfective therapy in cystic fibrosis.

Authors:  M S Zach; B Oberwaldner
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 8.  Airways reactivity in patients with CF.

Authors:  Miles Weinberger
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Primary ciliary dyskinesia: evolution of pulmonary function.

Authors:  J Hellinckx; M Demedts; K De Boeck
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

Review 10.  Cystic fibrosis.

Authors:  M R Bye; J M Ewig; L M Quittell
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.